Navigation Links
Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
Date:1/29/2013

s, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

About Keryx Biopharmaceuticals, Inc. 

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to submit an NDA with the FDA and a MAA with the EMA in the second quarter of 2013.  Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease.  Keryx is headquartered in New York City. 

KERYX CONTACT: 
Lauren Fischer 
Director - Investor Relations 
Keryx Biopharmaceuticals, Inc. 
Tel: 212.531.5965 
E-mail: lfischer@keryx.com 

 

 


'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
6. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
7. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
8. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
9. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
10. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
11. Generex Announces Details of Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... ANGELES , Oct. 30, 2014 Migranade, ... Relief will be available to the 36 million U.S. ... a platform technology that targets the actual cause of ... medications attack pain and not the source Migranade is ... medication category. MIGRANADE Migraine Relief is available at ...
(Date:10/31/2014)... Oct. 31, 2014 Though therapies are in ... expected to show an annual increase of 16.2% over ... nearly $1 billion, according to Kalorama Information,s report, ... stem cell therapeutics that have gained or are expected ... "As drug developers tackle ever more complicated conditions, stem ...
(Date:10/30/2014)... 30, 2014 Stryker Orthopaedics, the Official Joint ... is rounding out its debut year of the relationship ... Scottsdale, AZ. This marks the eleventh tournament ... that the brand has activated on-site with the "Stryker ... fans on the importance of joint health.  ...
Breaking Medicine Technology:Game Changing Migraine Medication To Be Available November 2014 2Report: Stem Cell Technologies Market Growing 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4
... 2011 eCardio Diagnostics ( www.ecardio.com ) announces three executive ... of its clients and the patients they serve. ... year has provided us with an opportunity to expand the ... Larry Lawson, President & Chief Executive Officer. Robert ...
... Reportlinker.com announces that a new market ... Medical Devices Reports Bundle ... The Medical Devices Reports Bundle includes ... discount off the individual reports being purchased separately: ...
Cached Medicine Technology:Reportlinker Adds Medical Devices Reports Bundle 2Reportlinker Adds Medical Devices Reports Bundle 3Reportlinker Adds Medical Devices Reports Bundle 4Reportlinker Adds Medical Devices Reports Bundle 5Reportlinker Adds Medical Devices Reports Bundle 6Reportlinker Adds Medical Devices Reports Bundle 7Reportlinker Adds Medical Devices Reports Bundle 8Reportlinker Adds Medical Devices Reports Bundle 9
(Date:10/31/2014)... and cost, patients with early stage breast cancer ... with proton therapy versus whole breast irradiation (WBI), ... Texas MD Anderson Proton Therapy Center. ... typical patient characteristics, researchers used Medicare reimbursement codes ... of partial and whole breast irradiation therapies and ...
(Date:10/31/2014)... Nearly one out of four older Americans say that ... or unwanted medical treatment, according to the latest issue ... & Aging Report ( PP&AR ), which goes ... accountable when they fail to honor patients, end-of-life health ... Advanced Illness Care: Issues and Options ," features 12 ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Gold Medal ... to find affordable but tasteful gifts for the wine novice ... Early Bird Gift Giving Special , which Early Bird ... they purchase Wine Club Gift membership. , Gift Givers ... of this special. Besides offering discounts, Gold Medal Wine Club ...
(Date:10/31/2014)... North Shore Eye Care today announced the ... and the addition of leading ophthalmologist, William S. Kasper, ... Shore Eye Care Medical Director, Jeffrey Martin, MD. , ... Department of Ophthalmology of Winthrop-University Hospital and has maintained ... more than 30 years. He has been named to ...
(Date:10/31/2014)... RESEARCH UK scientists have found a drug combination that ... - paving the way for new treatments, according to ... Research Institute (NCRI) Cancer Conference in Liverpool next week*. ... initiate a chain of events culminating in self destruction. ... and become immortal. This means that cells grow out ...
Breaking Medicine News(10 mins):Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Advance directives can benefit patients, families, and health care system 2Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... based venture-backed technology startup has been selected to ... (WEC25). The WEC25 Expo is an opportunity for ... a vast network of VCs and entrepreneurs. Delfigo ... identity and access management industry to offer a ...
... Wash., Feb. 4 drugstore.com , inc.,(Nasdaq: ... beauty, vision, and,pharmacy products, today announced its financial results ... 2008. The company reported,quarterly net sales of $93.9 ... fourth quarter gross margins of 28.5% and the highest ...
... Innovations, Inc.,(Nasdaq: YDNT ) today announced results for ... Sales for the fourth quarter of 2008 were ... $25.0 million reported in the fourth quarter,of 2007. Income ... of 2007 to $4.8 million in the fourth quarter of ...
... Andrew Cuomo and MVP Health Care today announced an ... not-for-profit organization to gather, maintain, and analyze provider reimbursement ... pay out of network providers using usual, customary and ... first involving an upstate New York based health insurer. ...
... 4 Pharmaceutical Research and Manufacturers of America ... following statement today regarding the State Children,s Health ... an expansion of the State Children,s Health Insurance ... of low-income, uninsured American families and, indeed, for ...
... might lead to better diagnosis and drug treatments, study ... who have the most common form of mental retardation ... a genetic mutation that may contribute to the condition, ... is that it occurs during development of the child ...
Cached Medicine News:Health News:Delfigo Security Selected as One of Twenty Five Most Promising Startups by The Wharton Entrepreneurship Conference 2Health News:Delfigo Security Selected as One of Twenty Five Most Promising Startups by The Wharton Entrepreneurship Conference 3Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 2Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 3Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 4Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 5Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 6Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 7Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 8Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 9Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 10Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 11Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 12Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 13Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 14Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 15Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 16Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 17Health News:drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales 18Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 2Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 3Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 4Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 5Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 6Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 7Health News:MVP Health Care is First Upstate New York Based Health Insurer to Agree with Attorney General Andrew Cuomo on Out-Of-Network Provider Payment Reform 2Health News:PhRMA Statement on Expansion of SCHIP 2Health News:Gene Mutation Tied to Majority of Cases of Mental Retardation 2
22 mm. Plastic, methylmethacrylate, lightweight. Supplied sterile....
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
Size: Large. 24.50 mm by 26.00 mm. Clear lucite. Supplied sterile....
... Size: 2.3 x 6.4 x 80 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
Medicine Products: